Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Nobel Prize for work in immunology/T cells Exce

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 157708
(Total Views: 266)
Posted On: 10/06/2025 1:50:38 PM
Posted By: dfwl28
Nobel Prize for work in immunology/T cells

Excerpt: ...After years of arduous work, the two researchers found the gene, called FOXP3. I t resembled others that control other genes. And, in 2001, they reported that a rare autoimmune disease in humans called IPEX was the same as the disease in mice.

Without FOXP3, regulatory T cells do not form. The body does not make T cells that tell other T cells that can attack the body’s cells not to respond.

“This is a great recognition of the fundamental importance of distinguishing self from non-self,” said John Wherry, director of the Colton Center for Autoimmunity at the University of Pennsylvania.

Cancers block attacks from the immune system by attracting a thicket of regulatory T cells. With the FOXP3 gene identified, and its role understood, researchers can develop drugs to turn the immune system against these cancer cells.



With autoimmune diseases, there is the opposite problem. Regulatory T cells are missing or defective. Using FOXP3 as a starting point, researchers are developing drugs to teach the immune system to stop its attack.

Dr. Marcela Maus, director of the cellular immunotherapy program at Massachusetts General Hospital, said the work “holds tremendous potential for unlocking new therapeutic avenues in medicine.”

“The holy grail has been to be able to manipulate and control immunity versus tolerance," Dr. Maus said. “The work of these laureates unlocked the tolerance side of this equation.”

With the discoveries, Dr. Wherry said, “major sets of drugs are going into the clinic,” for preliminary testing in cancer and autoimmunity.

https://www.nytimes.com/2025/10/06/health/nob...ology.html


(1)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us